Nkarta Inc (NKTX)

[jondoeuk]

The company has signed a lease agreement for a facility to support research and development and future commercial manufacturing of the company's cell therapy pipeline. The 88K square foot facility in South San Francisco will support scaled manufacturing of Nkarta's engineered NK cell therapy candidates. The new facility will also serve as the company's headquarters with office space and research facilities. At full capacity, it is expected to have the flexibility to produce commercial supply of multiple cell therapy products, the company said. The newly leased facility will be built-out as a multi-product facility and is expected to be operational by the end of 2023.